These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2440468)

  • 1. Plasma antipyrine half-life can be determined from urine data.
    Atiba JO; Taylor G; Pershe RA; Blaschke TF
    Br J Clin Pharmacol; 1987 Jun; 23(6):715-9. PubMed ID: 2440468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipyrine: radioimmunoassay in plasma and saliva following administration of a high dose and a low dose.
    Chang RL; Wood AW; Dixon WR; Conney AH; Anderson KE; Eiseman J; Alvares AP
    Clin Pharmacol Ther; 1976 Aug; 20(2):219-26. PubMed ID: 947654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.
    Danhof M; van Zuilen A; Boeijinga JK; Breimer DD
    Eur J Clin Pharmacol; 1982; 21(5):433-41. PubMed ID: 7075648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial measurements of plasma half-lives and urinary excretion of antipyrine in low-birth-weight infants.
    Murdock AI; Thorgeirsson SS; Rossiger H; Davies DS
    Biol Neonate; 1975; 27(5-6):289-301. PubMed ID: 1174600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of antipyrine kinetics by measurement in saliva.
    Fraser HS; Mucklow JC; Murray S; Davies DS
    Br J Clin Pharmacol; 1976 Apr; 3(2):321-5. PubMed ID: 973966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.
    Danhof M; de Groot-van der Vis E; Breimer DD
    Pharmacology; 1979; 18(4):210-23. PubMed ID: 461498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.
    Vesell ES; Passananti GT; Glenwright PA; Dvorchik BH
    Clin Pharmacol Ther; 1975 Sep; 18(3):259-72. PubMed ID: 1164816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.
    van Boxtel CJ; Wilson JT; Lindgren S; Sjöqvist F
    Eur J Clin Pharmacol; 1976 Feb; 9(4):327-32. PubMed ID: 971716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of antipyrine kinetics from saliva or plasma: influence of age.
    Jorquera F; Almar MM; Jimeno A; González-Sastre M; González-Gallego J
    J Pharm Biomed Anal; 1995 Aug; 13(9):1141-5. PubMed ID: 8573640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man.
    Daneshmend TK; Warnock DW; Ene MD; Johnson EM; Parker G; Richardson MD; Roberts CJ
    J Antimicrob Chemother; 1983 Aug; 12(2):185-8. PubMed ID: 6311786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.
    Vesell ES; Page JG
    J Clin Invest; 1969 Dec; 48(12):2202-9. PubMed ID: 5389794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of antipyrine pharmacokinetics in saliva and plasma using a colourimetric method of antipyrine analysis.
    Harman AE; Priestly BG; Frewin DB
    Clin Exp Pharmacol Physiol; 1977; 4(6):593-6. PubMed ID: 589875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immediate decrease by hydrocortisone of the plasma half-life of antipyrine.
    Breckenridge A; Burke CW; Davies DS; Orme ML
    Br J Pharmacol; 1973 Feb; 47(2):434-6. PubMed ID: 4722054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance.
    Elin RJ; Vesell ES; Wolff SM
    Clin Pharmacol Ther; 1975 Apr; 17(4):447-57. PubMed ID: 1122686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impairment of antipyrine clearance in humans by propranolol.
    Greenblatt DJ; Franke K; Huffman DH
    Circulation; 1978 Jun; 57(6):1161-64. PubMed ID: 639239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of antipyrine from saliva as a measure of metabolism in man.
    Welch RM; DeAngelis RL; Wingfield M; Farmer TW
    Clin Pharmacol Ther; 1975 Sep; 18(3):249-58. PubMed ID: 1164815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The plasma half-life of antipyrine in chromic uraemic and normal subjects.
    Maddocks JL; Wake CJ; Harber MJ
    Br J Clin Pharmacol; 1975 Aug; 2(4):339-43. PubMed ID: 1233993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsomal enzymes in malnutrition as determined by plasma half life of antipyrine.
    Krishnaswamy K; Naidu AN
    Br Med J; 1977 Feb; 1(6060):538-40. PubMed ID: 843795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anomalous results of studies on drug interaction in man. III. Disulfiram and antipyrine.
    Vesell ES; Passananti T; Glenwright PA
    Pharmacology; 1975; 13(6):481-91. PubMed ID: 1221431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.